CD274 and non-small cell lung carcinoma: More recently, an abstract presented at the American Association for Cancer Research (AACR) 2024 meeting reported outcomes for 50 patients who had received pembrolizumab and necitumumab combination treatment in the first-line setting for advanced NSCLC with PD-L1 expression of more than 50% [14].